Neoral (cyclosporine) labeling for psoriasis recommends biweekly creatinine, hypertension monitoring.
Executive Summary
NOVARTIS NEORAL PSORIASIS PATIENT BIWEEKLY CREATININE, BLOOD PRESSURE MONITORING recommended for the first three months of treatment, revised labeling states. Monitoring of blood urea nitrogen, complete blood count, uric acid, potassium, lipids and magnesium is also recommended biweekly for the first three months of psoriasis therapy, labeling states. Monthly monitoring is appropriate after the first three months of therapy, labeling adds. FDA approved the new indication for cyclosporine in June and Novartis expects to begin promoting the use by the end of the year ("The Pink Sheet" June 30, T&G-1).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth